RT Book, Section
A1 Guffey, William Joshua
A1 Phillips, Beth Bryles
A2 Sutton, S. Scott
SR Print(0)
ID 7250490
T1 Chapter 6. Anticoagulation/Venous Thromboembolism
T2 McGraw-Hill's NAPLEX® Review Guide
YR 2011
FD 2011
PB The McGraw-Hill Companies
PP New York, NY
SN 978-0-07-175562-7
LK accesspharmacy.mhmedical.com/content.aspx?aid=7250490
RD 2024/04/19
AB Venous  thromboembolism  (VTE)  is  a  significant  cause  of  morbidity  and  mortality  in  the  United  States.  Each  year  approximately  2  million  people  develop  VTE  and  60,000  of  these  are  fatal.1  The  economic  burden  to  the  health-care  system  is  roughly  $1.5  billion/year.2  VTE  encompasses  both  deep  venous  thrombosis  (DVT)  and  pulmonary  embolism  (PE).  The  mainstay  of  treatment  for  VTE  is  anticoagulant  agents.  Anticoagulants  are  also  used  short  and  long  term  to  prevent  thromboembolic  events,  including  those  associated  with  cardiac  valve  replacement  and  myocardial  infarction,  thromboembolic  stroke  related  to  atrial  fibrillation,  high-risk  hospitalized  patients,  and  high-risk  patients  undergoing  surgery.